Difference between revisions of "CT Angiography Biomarker Ctte"
Jump to navigation
Jump to search
(Created page with "Co-chair: Andrew Buckler, MS Secretary: Julie Lisiecki ==Meetings== '''Recent Call Summaries:''' ==Project Snapshot - CT Angiography== The group intends to pursue writing...") |
m |
||
| (97 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
| − | Co- | + | '''Co-chairs''': Andrew Buckler, MS, PhD; Luca Saba, MD; Uwe Joseph Schoepf, MD, FAHA, FSCBT-MR, FNASCI, FSCCT |
| + | |||
| + | * [http://tinyurl.com/QIBA-CT-Angiography-Roster Roster] | ||
| − | |||
==Meetings== | ==Meetings== | ||
'''Recent Call Summaries:''' | '''Recent Call Summaries:''' | ||
| + | |||
| + | *[[Media:2023_06-27_QIBA_CT_Angiography-FINAL.pdf| June 27, 2023]] | ||
| + | *[[Media:2023 03 28 QIBA CT Angiography FINAL.pdf| March 28, 2023]] | ||
| + | *[[Media:2023 03 14 QIBA CT Angiography FINAL.pdf| March 14, 2023]] | ||
| + | *[[Media:2023 02 14 QIBA CT Angiography FINAL.pdf| February 14, 2023]] | ||
| + | |||
| + | '''''[[CT Angiography Call Summaries Archive]]''''' | ||
==Project Snapshot - CT Angiography== | ==Project Snapshot - CT Angiography== | ||
| − | The group intends to pursue writing quantitative profiles for both Coronary computed tomography angiography (CCTA) and CT angiography (CTA). | + | The group intends to pursue writing quantitative profiles for both Coronary computed tomography angiography (CCTA) and CT angiography (CTA). |
Excerpt from the biomarker committee submission form: | Excerpt from the biomarker committee submission form: | ||
| − | The | + | The QIBA Atherosclerosis Biomarkers Committee (ABC) is organized to document quantitative profiles for both Computed Tomography Angiography (CTA) and Coronary CTA (CCTA). The membership is composed of participants from multiple centers of excellence within North America and Europe utilizing different CTA vendors, acquisitions and scanner types, and analysis software vendors. Representatives from different manufacturers are included in the committee, who are interested in working closely with the committee in optimizing imaging biomarkers for scientific trials and clinical routine use. The Biomarker Committee develops technical performance standards to serve as atherosclerosis compositional biomarkers, engaging stakeholders from different societies, in addition to the RSNA, for example ASNR, SCCT, ACR, etc. |
| + | |||
| + | ==Profile Development== | ||
| + | |||
| + | *[[Media:QIBA CTA Profile as of 2023-Feb-16.pdf|QIBA Atherosclerosis Biomarkers Profile Draft]] | ||
| + | *[[Media:QIBA CTA Profile as of 2020-Mar-10.pdf|QIBA Atherosclerosis Biomarkers Profile Draft]] | ||
| + | *[[Media:QIBA CTA Field Test Checklist.xlsx|QIBA Atherosclerosis Checklists]] | ||
| + | *[[Media:Atherosclerosis Biomarkers Profile 2019-11-27-full.PDF| QIBA Atherosclerosis Biomarkers Profile Draft]] | ||
| + | *[[Media:Atherosclerosis Biomarkers Profile 2019-11-27.PDF| QIBA Atherosclerosis Biomarkers Profile Draft (reduced page count)]] | ||
| + | *[[Media:CTA Comments 2019-11-27.xlsx| QIBA Atherosclerosis Biomarkers Profile Comments Spreadsheet]] | ||
| + | |||
| + | *[[Media:Atherosclerosis Biomarkers Profile 2019-10-30.PDF| QIBA Atherosclerosis Biomarkers Profile Draft]] | ||
| + | *[[Media:CTA Comments 2019-10-30.xlsx| QIBA Atherosclerosis Biomarkers Profile Comments Spreadsheet]] | ||
| + | |||
| + | *[[Media:Atherosclerosis Biomarkers Profile 2019-09-09b.PDF| QIBA Atherosclerosis Biomarkers Profile Draft]] | ||
| + | *[[Media:CTA Comments 2019-09-09.xlsx| QIBA Atherosclerosis Biomarkers Profile Comments Spreadsheet]] | ||
| + | |||
| + | *[[Media:Atherosclerosis Biomarkers Profile 2019-08-26.PDF| QIBA Atherosclerosis Biomarkers Profile Draft]] | ||
| + | *[[Media:CTA Comments 2019-08-26.xlsx| QIBA Atherosclerosis Biomarkers Profile Comments Spreadsheet]] | ||
| + | *[[Media:Atherosclerosis Biomarkers Profile 2019-08-12.PDF| QIBA Atherosclerosis Biomarkers Profile Draft]] | ||
| + | *[[Media:CTA Comments 2019-08-12.xlsx| QIBA Atherosclerosis Biomarkers Profile Comments Spreadsheet]] | ||
| − | + | *[[Media:Atherosclerosis Biomarkers Profile 2019-07-29.PDF| QIBA Atherosclerosis Biomarkers Profile Draft]] | |
| + | *[[Media:CTA Comments 2019-07-29.xlsx| QIBA Atherosclerosis Biomarkers Profile Comments Spreadsheet]] | ||
| + | *[[Media:Atherosclerosis Biomarkers Profile 2019-02-26.docx| QIBA Atherosclerosis Biomarkers Profile Draft]] | ||
| + | *[[Media:Atherosclerosis Biomarkers Profile 2019-02-11.docx| QIBA Atherosclerosis Biomarkers Profile Draft]] | ||
| + | *[[Media:2019 01-31 Atherosclerosis Biomarkers Profile-DRAFT.docx| QIBA Atherosclerosis Biomarkers Profile Draft]] | ||
| + | *[[Media:2019 01-14 Atherosclerosis Biomarkers Profile-DRAFT.docx| QIBA Atherosclerosis Biomarkers Profile Draft]] | ||
| + | *[[Media:2018 12-17 Atherosclerosis Biomarkers Profile-DRAFT.docx| QIBA Atherosclerosis Biomarkers Profile Draft]] | ||
| + | '''''[[Atherosclerosis Biomarkers Profile Draft Archive]]''''' | ||
==Groundwork Projects== | ==Groundwork Projects== | ||
| − | |||
==Reference Materials== | ==Reference Materials== | ||
| − | + | *[[Media:Biomarkers Selection Criteria.pdf| QIBA Biomarkers Selection Criteria Atherosclerosis Biomarker Committee (ABC) {Mr. Buckler}]] ''March 27, 2018'' (PDF) | |
==Conformance Materials== | ==Conformance Materials== | ||
Latest revision as of 18:40, 21 December 2023
Co-chairs: Andrew Buckler, MS, PhD; Luca Saba, MD; Uwe Joseph Schoepf, MD, FAHA, FSCBT-MR, FNASCI, FSCCT
Meetings
Recent Call Summaries:
CT Angiography Call Summaries Archive
Project Snapshot - CT Angiography
The group intends to pursue writing quantitative profiles for both Coronary computed tomography angiography (CCTA) and CT angiography (CTA).
Excerpt from the biomarker committee submission form:
The QIBA Atherosclerosis Biomarkers Committee (ABC) is organized to document quantitative profiles for both Computed Tomography Angiography (CTA) and Coronary CTA (CCTA). The membership is composed of participants from multiple centers of excellence within North America and Europe utilizing different CTA vendors, acquisitions and scanner types, and analysis software vendors. Representatives from different manufacturers are included in the committee, who are interested in working closely with the committee in optimizing imaging biomarkers for scientific trials and clinical routine use. The Biomarker Committee develops technical performance standards to serve as atherosclerosis compositional biomarkers, engaging stakeholders from different societies, in addition to the RSNA, for example ASNR, SCCT, ACR, etc.
Profile Development
- QIBA Atherosclerosis Biomarkers Profile Draft
- QIBA Atherosclerosis Biomarkers Profile Draft
- QIBA Atherosclerosis Checklists
- QIBA Atherosclerosis Biomarkers Profile Draft
- QIBA Atherosclerosis Biomarkers Profile Draft (reduced page count)
- QIBA Atherosclerosis Biomarkers Profile Comments Spreadsheet
- QIBA Atherosclerosis Biomarkers Profile Draft
- QIBA Atherosclerosis Biomarkers Profile Comments Spreadsheet
- QIBA Atherosclerosis Biomarkers Profile Draft
- QIBA Atherosclerosis Biomarkers Profile Comments Spreadsheet
- QIBA Atherosclerosis Biomarkers Profile Draft
- QIBA Atherosclerosis Biomarkers Profile Comments Spreadsheet
- QIBA Atherosclerosis Biomarkers Profile Draft
- QIBA Atherosclerosis Biomarkers Profile Comments Spreadsheet
- QIBA Atherosclerosis Biomarkers Profile Draft
- QIBA Atherosclerosis Biomarkers Profile Comments Spreadsheet
- QIBA Atherosclerosis Biomarkers Profile Draft
- QIBA Atherosclerosis Biomarkers Profile Draft
- QIBA Atherosclerosis Biomarkers Profile Draft
- QIBA Atherosclerosis Biomarkers Profile Draft
- QIBA Atherosclerosis Biomarkers Profile Draft
Atherosclerosis Biomarkers Profile Draft Archive
Groundwork Projects
Reference Materials
- QIBA Biomarkers Selection Criteria Atherosclerosis Biomarker Committee (ABC) {Mr. Buckler} March 27, 2018 (PDF)